Investigational drug · Phase 3
Vonaprument
Also called: ANX007
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Geographic Atrophy.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "Vonaprument"
First trial start
2024
Jul 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Vonaprument", any sponsor or status.
Conditions studied
As listed on its trial records.
- Geographic Atrophy
Approved drugs for the same conditions: Geographic atrophy
Largest trials
Live from ClinicalTrials.gov: studies naming "Vonaprument" as an intervention, largest first.
- A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)Pivotal-lookingActive, not recruiting
Annexon, Inc.Industry
NCT06510816 · 659 participants · Start Jul 30, 2024 · Primary completion Jul 31, 2027
Drug: Vonaprument · For: Geographic Atrophy
Sites: Scottsdale, Arizona; Beverly Hills, California; Fullerton, California · 132 sites in all
- An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)Pivotal-lookingNot yet recruiting
Annexon, Inc.Industry
NCT07807969 · 605 participants (planned) · Start Sep 30, 2026 · Primary completion Jul 31, 2029
Drug: Vonaprument · For: Geographic Atrophy
Sites: Sarasota, Florida; St. Petersburg, Florida; Hagerstown, Maryland · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Network Meta-Analysis of Complement Inhibitors for Geographic Atrophy in Age-Related Macular Degeneration.
Butt FR, Dhivagaran T, Tao BK, et al. · Surv Ophthalmol 2026
- Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma.
Sun Y, Wirta D, Murahashi W, et al. · Ophthalmol Sci 2023
- Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman Primates.
Grover A, Sankaranarayanan S, Mathur V, et al. · Invest Ophthalmol Vis Sci 2023
Also in development for Geographic Atrophy
- TinlarebantLBS-008Phase 33 trials
Belite Bio, Inc · Stargardt Disease 1, STGD1, Geographic Atrophy
- JNJ-81201887AAVCAGsCD59Phase 32 trials
Johnson & Johnson (Janssen) · Geographic Atrophy, Macular Degeneration
- OpRegenPhase 22 trials
Roche (Genentech) · Age-Related Macular Degeneration, Geographic Atrophy
- STL303Phase 22 trials
Sitala Bio LTD · IgAN, Geographic Atrophy
- ABBV-6628Phase 21 trial
AbbVie · Geographic Atrophy, Age-Related Macular Degeneration
- BI 1584862Phase 21 trial
Boehringer Ingelheim · Geographic Atrophy
- BI 771716Phase 21 trial
Boehringer Ingelheim · Macular Degeneration, Age-related, Geographic Atrophy
- BRX011Phase 21 trial
Biojiva LLC · Geographic Atrophy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.